Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07524777) titled 'Ganoderma Spores Modulate the Gut-Brain Axis' on April 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).

Primary Sponsor: Ling Zhiqiang

Condition: Depression Thyroid Cancer

Intervention: Dietary Supplement: Sporoderm-removed Ganoderma lucidum spore powder (RGLS)

Recruitment Status: Not recruiting

Phase: N/A

Date of First Enrollment: April 15, 2026

Target Sample Size: 300

To know more, visit https://clinicaltrials.gov/study/NCT07524777

Published by HT Digit...